Actively Recruiting
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Led by Riboscience, LLC. · Updated on 2026-04-24
220
Participants Needed
4
Research Sites
68 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
CONDITIONS
Official Title
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age on the day of signing informed consent
- Male or female participants with advanced, unresectable hepatocellular carcinoma eligible for STRIDE regimen as first line therapy
- Willingness to submit a pre-treatment tissue sample (archival or fresh if archival unavailable)
You will not qualify if you...
- BCLC stage D disease at screening or before first dose of RBS2418
- Child-Pugh class B8 or higher at screening or within 7 days before first study treatment dose
- Eligibility for curative treatments such as surgical resection, liver transplantation, or local ablation
- Evidence of rapid progression on prior therapy causing rapid clinical deterioration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Johns Hopkins
Baltimore, Maryland, United States, 21218
Actively Recruiting
2
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
3
University of Texas Southwestern
Dallas, Texas, United States, 75390
Actively Recruiting
4
START Dallas Fort Worth
Fort Worth, Texas, United States, 76104
Actively Recruiting
Research Team
R
Riboscience Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here